[ad_1]
New Delhi, Jul 2 (PTI) Dr. Reddy's Laboratories announced today that it has launched Repatha, a cholesterol-lowering drug, in the country after obtaining approval from the health regulator.
The company launched Repatha in the country, the first and only inhibitor of PCSK9, approved by the Drug Controller General India (DCGI), Dr. Reddy's Laboratories said in a statement
Repatha ( evolocumab) is a patented product of Amgen Global, indicated for the treatment of adult patients with primary hypercholesterolemia or mixed dyslipidemia
The product would be manufactured by Amgen and distributed by the Hyderabad-based company in the country
Repatha is used as an adjunct to diet in combination with a statin or a statin with other lipid-lowering therapies in patients who are unable to achieve LDL-C goals with the maximum tolerated dose of a statin.
"The launch of Repatha is another significant addition to Dr. Reddy's cardiovascular portfolio, which we believe wi ll provide a unique treatment option to patients in India who are at risk for heart attack, stroke. and coronary heart disease, "said MV Ramana, CEO of Dr. Reddy, Marked Markets (India and Emerging Markets)
up from RZ 2,241.05 to BSE PTI MSS MKJ MKJ
This is an unedited, unformatted stream from the Press Trust of India thread
.
[ad_2]
Source link
